IXICO plc Issue of 590,093 Deferred Consideration Shares (3643T)
05 January 2017 - 2:43AM
UK Regulatory
TIDMIXI
RNS Number : 3643T
IXICO plc
04 January 2017
4 January 2017
IXICO plc
("IXICO" or the "Company")
Issue of 590,093 Deferred Consideration Shares
IXICO, the brain health company, announces the issue of 590,093
ordinary shares of 1p each as Deferred Consideration in accordance
with the terms of the Share Purchase Agreement (the 'Agreement')
entered into between the Company and Optimal Medicine Limited on 18
November 2015.
Under the terms of the Agreement, the Deferred Consideration
Shares were to be issued on 4 January 2017 following the expiry of
the period during which the Company may bring a warranty claim and
the determination of the Board of Directors that no such warranty
claim is to be made by the Company.
Application has been made for the Deferred Consideration Shares
to be admitted to AIM on 9 January 2017. Upon admission of the
Deferred Consideration Shares to AIM, the enlarged issued share
capital of the Company will be 27,063,284 ordinary shares. The
Company does not hold any shares in treasury. Consequently,
27,063,284 is the figure which may be used by shareholders as the
denominator for the calculation by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the Company under the FCA's Disclosure and
Transparency Rules.
For further information please contact:
IXICO plc Tel: +44 20
Derek Hill, Chief Executive Officer 3763 7499
Susan Lowther, Chief Financial Officer
Shore Capital (Nomad and Broker) Tel: +44 20
Bidhi Bhoma / Edward Mansfield 7408 4090
FTI Consulting Limited (Investor Tel: +44 20
Relations) 3727 1000
Simon Conway/Mo Noonan/Matthew Moss
About IXICO
IXICO's innovative and proprietary digital healthcare
technologies help those involved in researching and treating
serious diseases to capture and analyse clinical data to make
rapid, informed decisions. In clinical research this includes the
phenotyping of patients, quantification of disease pathology and
measurement of patient outcomes. In clinical practice the mobile
health and digital decision support technologies aid diagnosis,
patient engagement and monitoring. IXICO is also collaborating with
partners to develop companion digital health products targeted at
improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease,
Huntington's disease, multiple sclerosis, Parkinson's disease,
behavioural health, child and adolescent mental health.
More information is available on www.ixico.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEEZLFBDFFXBBK
(END) Dow Jones Newswires
January 04, 2017 10:43 ET (15:43 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024